A complex disease, with many possible causes, compounded by a number of environmental risk factors, and deeply intertwined with a web of poverty, marginalisation and policy issues: pneumonia is exceptionally hard to tackle. No wonder progress to reduce its global burden has been slower than for other conditions. But in spite of those challenges, we believe this is a fight we can win.
Doctors often prescribe an antibiotic for children with pneumonia, but a new study suggests the drugs are not always needed.
Dr Chisti says that, as well as saving lives, his device has cut the hospital’s spending on pneumonia treatment by nearly 90%. The materials needed to make his version of a bubble-CPAP ventilator cost a mere $1.25. The device also consumes much less oxygen than a conventional ventilator.
Penicillin works well! Most children, even ones who require hospitalization, will benefit from a narrow spectrum penicillin.
In all pediatric age groups excluding neonates, viral pathogens are the most common etiology of pneumonia, with S. pneumoniae as the most common typical bacterial pathogen. M. pneumoniae detection increases with increasing age, particularly in children 5 years and older. Treatment for presumed bacterial pneumonia should begin with narrow-spectrum beta-lactams but broadening to third-generation cephalosporins may be appropriate in certain situation...
Each year, nearly 400,000 children under five years of age die globally from pneumococcal disease, mostly in Africa and Asia. WHO prequalification opens the door for this new vaccine, PNEUMOSIL®, to bolster the prevention toolkit and fulfill its purpose—to save more lives by enabling access that countries in these regions can afford and sustain long term.
Prevnar, the vaccine against the pneumococcus bacterium, is one of the greatest pharmaceutical innovations of the past two decades. In children who are vaccinated, it eliminated most of the pneumonia and meningitis that bacteria causes. It proved so effective, in fact, that fewer pneumococcal infections occur in people over 65 who have never gotten the vaccine, because the germs are no longer circulating. It has, quite simply, changed the world for the better.
Many people associate pneumonia with the elderly, but it is actually the biggest infectious killer of children worldwide. Every year, it claims the lives of more than 700,000 children under the age of 5, including over 153,000 newborns, who are particularly vulnerable to infection.
However, a breath of fresh air is now revitalising efforts to combat pneumonia in the form of a new international coalition bringing together more than 30 international institutions, including the ”la Caixa” Banking Foundation—one of the most important and coherent philanthropic actors in the field of pneumonia—and the Barcelona Institute for Global Health (http://www.isglobal.org/en).
A disease that claims the lives of two children under five a minute worldwide has hit drought-stricken Kenya hard, its spread driven by malnutrition.
It is critical to provide children with basic human needs like adequate nourishment, access to clean water and air, and equitable access to vaccines and basic healthcare. The costs associated with improving children’s living conditions must be evaluated against the high costs associated with the clinical management of childhood pneumonia. The residual burden of pneumonia can be reduced by prioritising child health through simple interventions. These include improving living conditions and accessibility to affordable medication, vaccines and care.
We have “eradication” targets for polio, “elimination” targets for malaria, and “generation-free” targets for HIV/AIDS, but for a disease that kills more children under five than all three combined, we have…well…very little.
The challenge for the emergency clinician is identifying the children who are more likely to have bacterial CAP and will benefit from antibiotic therapy while avoiding unnecessary testing and treatment in the majority of children who will have viral etiologies.
Viral pneumonias classically show perihilar bronchial thickening, interstitial opacities and hyperinflation. Bacterial pneumonias classically cause lobar consolidation.
The last century has been witness to vast medical advancements that have saved the lives of hundreds of millions of people around the world. Yet recent figures show that in 2015 alone, nearly a million children died of pneumonia. It is both astounding and saddening that despite the availability of simple provisions that can both prevent and cure the disease, marginalised children are being denied access to the right drugs to save their lives.
Children who live near a main road are in greater danger of catching pneumonia because pollution from passing traffic damages their lungs. A leading expert in childhood breathing difficulties has made the link between exposure to particles from vehicle exhausts and a child's susceptibility to the chest infection, which can be fatal.
Mark Alderson won’t rest easy until he solves one of the biggest problems in global health: a vaccine against pneumonia.
In 2013, WHO and UNICEF released the Integrated Global Action Plan for the Prevention and Control of Pneumonia and Diarrhoea, which set a target of less than three child pneumonia deaths per 1,000 live births in every country by 2025.
Pneumonia kills more children than any other infectious disease. Globally, close to 1 million under five children die from this preventable disease every year – the equivalent of more than 2,500 dying every day. That’s more than the death tolls of diarrhoea, malaria and HIV combined for this age group. Yet you will hear of no global campaign or cause to end pneumonia.
World’s first public-private partnership to support national governments to end preventable child pneumonia deaths by 2030.
Aiming to achieve unprecedented levels of collaboration to improve the quality, availability, and affordability of pneumonia prevention, diagnostic and treatment innovations for children.
Stopping pneumonia isn’t about luck. It’s about action. Stop Pneumonia is an initiative that provides a voice for communities who suffer from the devastating consequences of the disease and who lack access to lifesaving interventions.